Targeting rare tumors: new focus for clinical research in China
Abstract Rare tumor has a huge unmet medical need without standard regimens, calling for novel therapeutic interventions. The National Cancer Center of China identified a threshold of incidence for rare tumor as 2.5/100,000, based on the characteristics of Chinese population. Molecular profiles for...
Saved in:
| Main Authors: | Shuhang Wang, Yale Jiang, Huilei Miao, Yuan Fang, Ning Jiang, Yue Yu, Peiwen Ma, Qiyu Tang, Dandan Cui, Hong Fang, Huiyao Huang, Qi Fan, Chao Sun, Anqi Yu, Shuangman Miao, Jingting Du, Jingxiao Zhu, Yuning Wang, Ning Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2022-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202216415 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Challenging go/no-go decision scenarios and design recommendations in phase II oncology trials
by: Dandan Kong, et al.
Published: (2025-08-01) -
Reflections and insights into the evolution of restrictive eligibility criteria for cancer clinical trials in China and beyond
by: Huiyao Huang, et al.
Published: (2025-06-01) -
Clinical benefits of immune checkpoint inhibitors for malignant peripheral nerve sheath tumors with NF2 mutation: a case report
by: Yale Jiang, et al.
Published: (2025-05-01) -
Trends of drug licensing in China: From bring-in to go-global
by: Yale Jiang, et al.
Published: (2024-12-01) -
The state of the art of bispecific antibodies for treating human malignancies
by: Shuhang Wang, et al.
Published: (2021-08-01)